History

The history is the path EDGC has followed, and it will make way to the top.

History

2019

Feb. Launch ACMG59 in the USA
Sign the agreement of medical marijuana R&D with SCG

2018

Jan. Register for a patent (Method of Detecting Chromosomal Abnormalities)
Register for a patent (Novel Method Capable of Differentiating Fetal Sex and Fetal Sex Chromosome Abnormality on Various Platforms)

Mar. Sign the cooperation agreement between Company-IBK-University
Sign the cooperation agreement Human Project with Incheon National University

Apr. Launch MYGENPLAN®

Sign the sales contract for EyeGene® with AGBio Diagnostics and SCD Pharm
Awarded Best Technology Award of Incheon Scientific Technology Awards (Ph.D Sung-Hoon Lee)
Register for a patent (Method for Predicting Organ Transplant Rejection Using Next-Generation Sequencing)

May. Selected as AI-Based Precision Medicine Solution Bureau organized by the Ministry of Science and ICT
Selected as Distributed Bio-Health Big-Data Organization organized by the Ministry of Trade, Industry and Energy

Jun. Listed on Korea Securities Dealer Automated Quotation (KOSDAQ)

Jul. Sign the cooperation agreement of healthcare contents development with KoreaMedicare
Establish EDGC Asia in Hong Kong

Aug. Receive CAP Certificate
Sign the co-development and sales agreement for NGS-based product (SolGent)
Sign the co-development agreement of personalized skin diagnosis and solution based on genes (DOHU, XINMAY SKIN)
Sign the cooperation agreement with Medical Center of the Executive Office of the President of the Republic of Tajikistan

Sep. Undertake CNS Healthcare’s Stocks
Sign the contract for personalized language education business with EKYSS
Rank No.1 in Services/Manufacturing at Consumer Satisfaction Brand Awards
Sigh the cooperation agreement with Yancheng City, China

Oct. Sign the research agreement for genetic approach for Agent Orange victims with VAVA
Sign the cooperation agreement for genetic information protection with EVERSPIN
Appointed new CEO Myung-Hee Lee to EDGC Healthcare

Nov. Sign the cooperation agreement for expansion of Total care service converged with genetic analysis (HealthMax, Mediage)

2017

Feb. Launch bebegene®

Mar. Sign the cooperation agreement in the life sciences with Ghent University

Apr. Establish EDGC, Inc. in the United States of America

May. Launch MyEyeGene®

Jul. Sign the co-development agreement of precision diagnosis with Ewha Womans University Medical Center
Sign partnership agreement with GPBio
Sign partnership agreement with BRIA Lab

Sept. Launch Wine Matching Service
Apply for a patent (Method and System for Providing Personalized Wine Information by Gene Based on Individual and Terminal Using Same)

Oct. Participate in World Knowledge Forum – the session, titled ‘100 dollars genome’ as a moderator
Host the 2nd Personal Genome Revolution Seminar with Incheon National University
Launch gene2me® Plus

Nov. Announce to launch NIPT applying AI technology

Dec. Begin to provide NICE® through Cordlife branches in the Philippines and Indonesia
Begin to provide NICE® through BRIA Lab in Thailand
Sign the agreement for cooperation between industry and educational organizations with Incheon National University

2016

Jan. Apply for a patent (Method of Detecting Chromosomal Abnormalities)

Mar. Apply for a patent (Method for Diagnosing Fetal Chromosomal Aneuploidy)

Apr. Sign the memorandum of understanding for early cancer diagnosis (CytoGen)

May. Sign the research contract for organ transplant patient monitoring (B Hospital)

Jun. Selected as Global Screening Array (GSA) consortium’s partner
Sign the support agreement for human care contents development (Kyungpook National University)
Apply for a patent (Method for Determining the Presence or Absence of Aneuploidies and Copy Number Variations in a Sample by Using 2-Dimensional Distribution of Values)
Launch gene2me®

Aug. Sign the contract for diagnostic product development and sale activation with Genoheal
Sign the agreement for human resource development customized for local industry with Incheon National University
Sign the agreement of solution development based on genes with Genodoctor
Co-develop the genetic testing for personalized oriental medicine treatment with Familiar Hospital
Signed the co-development agreement of personalized cosmetics based on genetic testing for skin type
with LUI & LEI and Genoheal
Sign the agreement for long term work experience with Incheon National University

Sept. Introduce the matrix school system with Incheon National University
Register a patent (Biomarkers Indicative of Down Syndrome and Their Uses)

Nov. Sign the agreement for cooperation between industry and educational organizations with Incheon National University

Dec. Acquire CE certificate for NICE® Check Control Kit/LOD Kit
Acquire CE and KFDA certificate for NICE® Check cfDNA Tube

2015

Mar. Sign the development agreement for bioinformatics based on cloud with Maverix (USA)

Apr. Apply for a patent (Method for Predicting Organ Transplant Rejection Using Next-Generation Sequencing)

Aug. Apply for a patent (Novel Method Capable of Differentiating Fetal Sex and Fetal Sex Chromosome Abnormality on Various Platforms)

Oct. Launch NICE® Check Control/LOD/cfDNA Tube at 2015 ASHG

Nov. Launch NICE®, CLIA-Certified Non-Invasive Prenatal Test (NIPT)

2014

Jan. Acquire Company Annex Research Institute Certificate (No. 2014110065)

May. Apply for a patent (Biomarkers Indicative of Down Syndrome and Their Uses)

Jul. Launch Verifi®, Illumina’s Non-Invasive Prenatal Test (NIPT) domestically for the first time
Sign the joint research agreement on Hospital Acquired Infection (HAI) with Bioinnovation (Swiss)

Dec. Organize Organ Transplant Rejection Monitoring Project with Pennsylvania University and Cornell University
Develop BRCARE®, female cancer prediction test

2013

May. Establish EDGC

Sept. Upload EDGC Annotator on Illumina’s BaseSpace

No posts found.